Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.86)
# 1,863
Out of 5,102 analysts
46
Total ratings
40%
Success rate
53.81%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NXTC NextCure | Upgrades: Buy | $18 | $11.69 | +53.98% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $10.00 | +50.00% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $2.45 | +675.51% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $13.22 | +126.93% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.18 | +1,764.41% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $9.27 | +158.90% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $27.25 | +358.72% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $3.41 | +427.86% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.40 | +458.82% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $2.33 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $192.96 | -58.97% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $101.25 | +53.09% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.57 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $10.94 | +128.52% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $6.37 | +28,157.46% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $37.64 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.56 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.63 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $4.02 | +37,213.43% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.68 | +53,471.43% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $6.74 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $14.49 | +1,038.72% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $219.60 | +2.46% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $7.23 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.82 | - | 2 | Jan 4, 2017 |
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $11.69
Upside: +53.98%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $10.00
Upside: +50.00%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.45
Upside: +675.51%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $13.22
Upside: +126.93%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.18
Upside: +1,764.41%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $9.27
Upside: +158.90%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $27.25
Upside: +358.72%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $3.41
Upside: +427.86%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.40
Upside: +458.82%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.33
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $192.96
Upside: -58.97%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $101.25
Upside: +53.09%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $8.57
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $10.94
Upside: +128.52%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $6.37
Upside: +28,157.46%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $37.64
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.56
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.63
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $4.02
Upside: +37,213.43%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.68
Upside: +53,471.43%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $6.74
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $14.49
Upside: +1,038.72%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $219.60
Upside: +2.46%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $7.23
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $1.82
Upside: -